Table 3.

Research questions for future translational research

1. Which NET-associated proteins are specifically present on AAV- and SLE-induced NETs as identified through proteomics?

2. Could the quantification of NET formation serve as a biomarker for disease activity and prognosis in relation to conventional and novel therapies in AAV and SLE patients?

3. Which targets can be identified that are capable of regressing excessive NET formation or increase NET degradation that could translate to a therapeutic approach in AAV and SLE?

AAV, antineutrophil cytoplasmic antibodies (ANCA)− associated vasculitis; NET, neutrophil extracellular trap; SLE, systemic lupus erythematosus.